Montana Advances Experimental Drug Rules

Montana has advanced its plan to become a hub for experimental medical treatments, with new regulations taking effect this week. Biotech companies that have completed preliminary drug testing, which may involve as few as 10 healthy individuals, can now apply for approval through a newly established review board. The application fee for this process is set at $12,500. Once a treatment receives approval from this board, companies will be permitted to sell it through experimental treatment clinics. The first of these clinics is anticipated to be operational by the end of the current year. This new legislation, referred to as Montana's "right to try" law, is unique in its approach to drug access. Theoretically, any individual who provides informed consent and can afford the treatment can access these experimental drugs. This prospect is viewed with hope and excitement by some, particularly within the longevity community, who see it as a potential pathway to novel therapies. However, the initiative has also drawn criticism from others who deem it unethical and potentially dangerous due to the early stage of the drugs being offered.

One individual facing the urgent need for experimental treatments is Kris DeVault, whose son, Brody, was born in March 2023. Brody suffers from creatine transporter deficiency, a rare condition that impairs the development of the brain and muscles due to a lack of energy. Currently, there are no known cures for this condition. DeVault has identified a company developing a drug that shows potential for Brody's condition. This drug is still in its nascent stages of development, having undergone testing only in animals and a limited number of healthy adult volunteers. As such, it is not yet available for prescription by doctors. Despite the uncertainties surrounding its efficacy, DeVault is actively pursuing access to this experimental treatment, illustrating the profound personal stakes involved in such legislative changes. The development is detailed in a story from The Checkup, a weekly biotech newsletter.

This initiative positions Montana as a state willing to explore alternative pathways for drug development and patient access, diverging from traditional, lengthy regulatory processes. The $12,500 application fee and the requirement for preliminary testing aim to provide a structured, albeit expedited, framework for companies seeking to bring their experimental therapies to market. The establishment of dedicated experimental treatment clinics signifies a commitment to creating accessible points of care for patients who qualify under the new "right to try" provisions. The timeline for the first clinic to open by year-end underscores the state's intent to rapidly implement these new policies. The dual reception of the law—as a beacon of hope for some and a cause for concern for others—highlights the complex ethical considerations inherent in balancing innovation with patient safety in the realm of advanced medical treatments.